Climate Change Data

Idorsia Pharmaceuticals Ltd

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:982.8 tCO2e (Scope 1 & 2)
Scope 1 Emissions:475.0 tCO2e
Scope 2 Emissions:507.8 tCO2e
Scope 3 Emissions:Not disclosed
Renewable Energy Share:100% (headquarters electricity)
Total Energy Consumption:15781 MWh
Water Consumption:33.68 ML
Waste Generated:305.1 tons
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Advancing science and healthcare
  • Safeguarding and developing talent and fostering diversity
  • Compliance and business ethics
  • Environmental impact management

Environmental Achievements

  • Substantially reduced carbon emissions since founding (specific figures not provided, but a 65% reduction by 2023 compared to 2016 is mentioned for Switzerland, and a 90%+ reduction in oil consumption since 2018 due to woodchip burner installation)
  • 100% hydropower electricity supply at headquarters in 2023
  • Reduced total waste by 44 tons compared to 2022 (12.7% reduction)

Social Achievements

  • Launched QUVIVIQ™ in several markets across the EU and secured reimbursement from significant US payors
  • Implemented an all-employee equity program ('Ambition 2027')
  • Offered various programs to support employee mental health and well-being globally
  • Proactive gender pay equity analysis conducted and results confirming equal pay published

Governance Achievements

  • Established a robust governance framework including policies, standard operating procedures, and guidelines to drive a culture of integrity
  • Implemented mandatory training on Code of Business Conduct for all employees
  • Incorporated climate-related risks into the Enterprise Risk Management (ERM) process

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Increase energy efficiency by 4.7% and decrease CO2 emissions by 20% at headquarters from 2016 to 2025 (agreement with Federal Offices for the Environment and Energy)
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • Financial challenges impacting ability to invest in new sustainability initiatives, collect data, and monitor impact
  • Staff reductions due to financial constraints
  • Lower-than-anticipated product sales and a difficult global financial environment
Mitigation Strategies
  • Sold operating businesses in Asia-Pacific (excluding China) to give the company more time to create sustainable value
  • Strengthened innovative portfolio by reacquiring worldwide rights to aprocitentan
  • Focused on activities crucial to maximizing the time the company has to deliver commercial success with its products

Supply Chain Management

Supplier Audits: 22 (82%) of key suppliers assessed for environmental and social impacts through IntegrityNext

Responsible Procurement
  • Use of IntegrityNext platform for supplier qualification and monitoring
  • Screening of suppliers based on social and environmental criteria (anti-bribery, environmental protection, human rights, conflict minerals, etc.)

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: GRI 2021 Standards, TCFD (initial assessment completed)

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed